Novo Nordisk A/S Sponsored ADR Class BNovo Nordisk A/S Sponsored ADR Class BNovo Nordisk A/S Sponsored ADR Class B

Novo Nordisk A/S Sponsored ADR Class B

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪224.64 B‬EUR
3.09EUR
‪14.15 B‬EUR
‪40.68 B‬EUR
‪3.37 B‬
Beta (1Y)
1.28

About Novo Nordisk A/S Class B


CEO
Maziar Mike Doustdar
Headquarters
Bagsværd
Founded
1923
ISIN
US6701002056
FIGI
BBG000JPN1L2
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Check out other big names from the same industry as NOVA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
N
XS300255582
Novo Nordisk Finance (Netherlands) BV 3.625% 27-MAY-2037
Yield to maturity
3.56%
Maturity date
May 27, 2037
N
XS282046075
Novo Nordisk Finance (Netherlands) BV 3.375% 21-MAY-2034
Yield to maturity
3.28%
Maturity date
May 21, 2034
N
XS300255353
Novo Nordisk Finance (Netherlands) BV 3.125% 27-MAY-2033
Yield to maturity
3.10%
Maturity date
May 27, 2033
N
XS282045567
Novo Nordisk Finance (Netherlands) BV 3.25% 21-JAN-2031
Yield to maturity
2.90%
Maturity date
Jan 21, 2031
N
XS300255329
Novo Nordisk Finance (Netherlands) BV 2.875% 27-AUG-2030
Yield to maturity
2.83%
Maturity date
Aug 27, 2030
XS244124704
Novo Nordisk Finance (Netherlands) BV 1.375% 31-MAR-2030
Yield to maturity
2.72%
Maturity date
Mar 31, 2030
N
XS282045460
Novo Nordisk Finance (Netherlands) BV 3.125% 21-JAN-2029
Yield to maturity
2.62%
Maturity date
Jan 21, 2029
N
XS300255299
Novo Nordisk Finance (Netherlands) BV 2.375% 27-MAY-2028
Yield to maturity
2.61%
Maturity date
May 27, 2028
XS234803042
Novo Nordisk Finance (Netherlands) BV 0.125% 04-JUN-2028
Yield to maturity
2.45%
Maturity date
Jun 4, 2028
N
XS282044994
Novo Nordisk Finance (Netherlands) BV 3.375% 21-MAY-2026
Yield to maturity
2.41%
Maturity date
May 21, 2026
XS244933017
Novo Nordisk Finance (Netherlands) BV 1.125% 30-SEP-2027
Yield to maturity
2.35%
Maturity date
Sep 30, 2027

See all NOVA bonds 

PPH
VanEck Pharmaceutical ETF
Weight
7.89%
Market value
‪55.58 M‬
USD
AVDE
Avantis International Equity ETF
Weight
0.41%
Market value
‪40.61 M‬
USD
PID
Invesco International Dividend Achievers ETF
Weight
2.13%
Market value
‪18.53 M‬
USD
WCMI
First Trust WCM International Equity ETF
Weight
2.61%
Market value
‪15.87 M‬
USD
JAVA
JPMorgan Active Value ETF
Weight
0.31%
Market value
‪13.04 M‬
USD
PVAL
Putnam Focused Large Cap Value ETF
Weight
0.30%
Market value
‪12.74 M‬
USD
RVER
Trenchless Fund ETF
Weight
9.67%
Market value
‪9.82 M‬
USD
LIFE.B
Evolve Global Healthcare Enhanced Yield Fund
Weight
4.19%
Market value
‪8.77 M‬
USD

Explore more ETFs